Related Experiment Video
Updated: Dec 29, 2025

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
Wearing-off at the end of natalizumab dosing intervals is associated with low receptor occupancy
Gerd Haga Bringeland1, Nello Blaser2, Kjell-Morten Myhr2
1From the Neuro-SysMed (G.H.B., K.-M.M., C.A.V., S.G.), Department of Neurology, Haukeland University Hospital, Bergen, Norway; Department of Clinical Medicine (G.H.B., K.-M.M., C.A.V., S.G.), University of Bergen, Bergen, Norway; and Department of Informatics (N.B.), University of Bergen, Bergen, Norway. gerd.haga.bringeland@helse-bergen.no.
Objective:
We aimed to investigate whether wearing-off symptoms at the end of the natalizumab dosing interval were associated with clinical and demographic patient characteristics or natalizumab receptor occupancy (RO) on leukocytes.
Methods:
In this cross-sectional study of 40 patients with relapsing-remitting MS (RRMS) receiving natalizumab at the Department of Neurology, Haukeland University Hospital, we recorded clinical and demographic data including age, body mass index (BMI), working status, smoking habits, disease characteristics, treatment duration, vitamin D levels, and wearing-off symptoms. We quantified neurofilament light chain in serum and measured natalizumab RO in leukocyte subtypes by high-parameter mass cytometry. Associations with wearing-off symptoms were analyzed.
Results:
Eight (20.0%) patients who reported regular occurrence of wearing-off symptoms, 9 (22.5%) who sometimes had wearing-off symptoms, and 23 (57.5%) who did not have wearing-off symptoms were evaluated. Patients who regularly had wearing-off symptoms had lower natalizumab RO than patients who reported having such symptoms sometimes or never. The former group also had higher BMI and higher frequency of sick leave. High BMI was associated with low RO. No other demographic or disease characteristics were associated with the phenomenon.
Conclusions:
Low RO may explain the wearing-off phenomenon observed in some patients with RRMS treated with natalizumab, and high BMI may be the underlying cause.
Related Concept Videos
Quantitative Aspects of Drug-Receptor Interaction
Desensitization and Tachyphylaxis
Spare Receptors
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
Therapeutic Drug Monitoring: Affecting Factors
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

